Abstract: An analyzing device has one end of a supplying capillary channel opened at a spot application section formed so as to protrude from an analyzing device main body. The supplying capillary channel is connected to a microchannel structure formed inside the analyzing device main body. A sample liquid is applied to the spot application section and is suctioned by a capillary force of the supplying capillary channel. The analyzing device is used for reading in which a suctioned solution is accessed. The analyzing device includes a leading end of the spot application section that has an inclined face. The end of the supplying capillary channel is opened on the inclined face.

Abstract: The present invention relates to a method for determining a level of fat-free body mass (FFM) in a paediatric subject comprising determining a level of phenylacetylglutamine (PAG) in a sample obtained from the subject.

Abstract: System that makes nutritional recommendations based on results of a home urine test. A user may apply a urine sample to a card containing multiple tests, and capture an image of the card using a phone; an analysis system executing on the phone or in the cloud may analyze the image and determine test results. The test card and analysis system may compensate for variability in lighting conditions and time of exposure to the urine sample. Based on test results, the system may recommend consumption of specific quantities of nutrients, such as vitamins, minerals, and foods. It may also recommend consumption of water or electrolytes based on measured hydration, and stress reduction techniques or sleep based on measured cortisol. Recommendations may be customized based on factors such as the user's characteristics (gender, weight, etc.), predicted absorption of nutrients from food or supplements, and the user's dietary preferences or restrictions.

Abstract: The invention generally relates to assemblies for displacing droplets from a vessel that facilitate the collection and transfer of the droplets while minimizing sample loss. In certain aspects, the assembly includes at least one droplet formation module, in which the module is configured to form droplets surrounded by an immiscible fluid. The assembly also includes at least one chamber including an outlet, in which the chamber is configured to receive droplets and an immiscible fluid, and in which the outlet is configured to receive substantially only droplets. The assembly further includes a channel, configured such that the droplet formation module and the chamber are in fluid communication with each other via the channel. In other aspects, the assembly includes a plurality of hollow members, in which the hollow members are channels and in which the members are configured to interact with a vessel.

Abstract: Embodiments of the present disclosure pertain to methods of detecting a thiol in an environment by exposing the environment to a probe molecule that contains a marker and a thiol responsive group. The thiol responsive group reversibly reacts with the thiol in the environment to form a probe-thiol adduct. This in turn causes a ratiometric change in a spectrometric property of the probe molecule and the probe-thiol adduct, which can then be correlated to the presence of the thiol in the environment. The correlation can occur by quantifying the thiol concentration in the environment. In addition, thiol detection can occur in real-time. Further embodiments of the present disclosure pertain to probe molecules that are utilized for detecting a thiol in an environment. In some embodiments, the probe molecule includes a marker and a thiol responsive group. In some embodiments, the probe molecule also includes an organelle targeting moiety.

Abstract: Disclosed are a chemochromic nanoparticle, a method for manufacturing the chemochromic nanoparticle, and a hydrogen sensor comprising the chemochromic nanoparticle. In particular, the chemochromic nanoparticle has a core-shell structure such that the chemochromic nanoparticle and comprises a core comprising a hydrated or non-hydrated transition metal oxide; and a shell comprising a transition metal catalyst.

Abstract: The present disclosure provides a method for mapping one or more analytes that contact a biological structure. The method uses surface-enhanced Raman spectroscopy and includes contacting the biological structure and a metallic nanoparticle. The method further includes collecting a spectrum with a Raman spectrometer. The method further includes determining a location of the analyte along at least one of an x-direction, a y-direction and a z-direction on the structure.

Abstract: A sample analyzer is configured to execute a liquid surface detection of detecting a liquid surface in a container by a liquid surface detector prior to a lowering operation of an aspirating tube for aspirating the liquid if a liquid level information is not stored in a memory, and store a liquid level information of a container in the memory based on a detection result by the liquid surface detection. Also, a liquid aspirating method by a sample analyzer.

Abstract: Systems, techniques and methods for estimating the metabolic state or flux, e.g., the body energy state (“BES”) of a patient, are disclosed. The BES provides a deep insight into the nutritional needs of the patient, thus allowing for a sort of exquisite glycemic control with regard to the patient. The invention discloses systems and methods for estimating fractional gluconeogenesis. The invention also discloses systems and methods for estimating and targeting patient blood lactate concentration, both as a target itself and as an intermediate step to estimating and targeting patient fractional gluconeogenesis glucose production. Nutritional support methods and formulations are also disclosed. The invention is suitable for any sort of patient, including those who are injured, such as with traumatic brain injury, ill, or have other conditions that stress the metabolic system.

Abstract: A reagent analyzer and method is described. In the method, a reagent card having a reagent pad is passed through an optical signal path between an optical signal source and an optical signal detector. A transition between a first electrical signal and a second electrical signal is detected to determine a substantially exact position of a leading end or a trailing end of the reagent pad. The first electrical signal is indicative of the substrate interfering with the optical signal. The second electrical signal is indicative of the substrate and reagent pad of the reagent card interfering with the optical signal. The reagent pad is moved to a known second location upon determining the substantially exact position of at least one of the leading end and the trailing end of the reagent pad. At the second location a sample is dispensed onto the reagent pad by a sample dispenser.

Abstract: The present invention relates to a method of screening for renal cell carcinoma in a subject, said method comprising determining the level and/or chemical composition of one or both of the glycosaminoglycans (GAGs) chondroitin sulfate (CS) and heparan sulfate (HS) in a body fluid sample, wherein said sample has been obtained from said subject.

Abstract: Methods and systems for detecting environmental contaminants is described. In an embodiment, a method includes macerating and extracting a sample; reacting a first polymerizable compound with the sample to form a second mixture comprising a second polymerizable compound; adding an initiator to the second mixture comprising the second polymerizable compound; performing a polymerization reaction on the second mixture comprising the second polymerizable compound to form a third mixture comprising a precipitate; and performing a turbidimetric analysis on the third mixture comprising the precipitate. In another embodiment, a method includes macerating and extracting a sample; reacting a first mixture comprising the functionalized polythiophene compound and the sample to form a second mixture comprising a second functionalized polythiophene compound; performing a colorimetric analysis on the second mixture comprising the second functionalized polythiophene compound.

Abstract: An in vitro method for diagnosing a brain tumour in a human test subject comprising: determining the concentration of at least two metabolites comprised in a biofluid sample obtained from the human test subject; comparing the concentration of the at least two metabolites in the biofluid sample with the concentration of the same at least two metabolites in at least one reference standard obtained from a non-tumour bearing subject and/or a tumour bearing subject; and identifying a concentration difference for each of the at least two metabolites in the biofluid sample relative to the reference standard; wherein the concentration difference for each of the at least two metabolites in the biofluid sample correlates with the presence of a brain tumour. The invention also relates to a data-storage medium comprising data obtained by a method of the invention.

Abstract: Provided herein is a method for determining the volume or hemoglobin content of an individual red blood cell in a sample containing a population of red blood cells. The method may be performed on a hematology analyzer. Also provided are a hematology analyzer for performing the method and a computer-readable medium containing programming for performing the method.

Abstract: The present invention addresses the problem of developing an analytical method which makes it possible to diagnose early or mild renal disorders. The method is based on calculating a disease-state index value for renal disorders on the basis of the quantities of D-form and/or L-form amino acids, from feces or intestinal content. By comparing the disease-state index value with a threshold value determined from the disease-state index values of a renal failure patient group and a healthy subject group, it is possible to diagnose a mild renal disorder patient group.

Abstract: Biomarkers and/or risk assessments identify patients having an increased risk of certain clinical disease states including, for example, CHD, type 2 diabetes, dementia, or all-cause death (ACD) using NMR signal to measure a level of “GlycA” in arbitrary units or in defined units (e.g., ?mol/L) that can be determined using a defined single peak region of proton NMR spectra. The GlycA measurement can be used as an inflammation biomarker for clinical disease states. The NMR signal for GlycA can include a fitting region of signal between about 2.080 ppm and 1.845 ppm of the proton NMR spectra.

Abstract: A cancer evaluation method includes a step S1 of measuring the concentrations of a set of evaluation elements in a serum sample 2 taken from a subject, a step S2 of applying the concentration data of the set of elements to a predetermined discriminant function to perform an operation; and a step S3 of discriminating whether or not the subject suffers from any type of cancer based on the operation result obtained using the concentration data and the discriminant function. The discrimination is carried out in accordance with the concentration balance (pattern) of the set of elements. Preferably, the set of elements are 7 elements of S, P, Mg, Zn, Cu, Ti, and Rb, or 16 elements of Na, Mg, Al, P, K, Ca, Ti, Mn, Fe, Zn, Cu, Se, Rb, Ag, Sn, and S.

Abstract: A method for recalculating the solvent power of a light oil, SP(LO recalculated), is provided.

Abstract: Particular aspects of the invention are methods for assaying metabolite levels in samples from a patient during pregnancy using nuclear magnetic resonance and direct flow injection mass spectrometry. In various methods, the assayed metabolites may be acylcarnitine or one or more of C3-OH (hydroxypropionylcarnitine), C5-OH (C3DC), C10, C5:1-DC (glutaconylcarnitine), C14:1-OH (hydroxytetradecenoylcarnitine) and C14:2-OH. One or more methods also may include measuring nuchal translucency of the fetus. Other methods relate to predicting fetal congenital heart defects in a fetus.

Abstract: Embodiments of the present disclosure describe a gas sensor comprising a gas-sensing material including a metal-organic framework with fcu topology and a substrate with a pair of electrodes proximate to the gas-sensing material, wherein the gas sensor is configured to detect toxic gas. Embodiments of the present disclosure further describe a method of detecting gas comprising contacting a gas sensor including a metal-organic framework with fcu topology with a gas/vapour composition including at least one toxic gas, capturing the at least one toxic gas from the fluid composition, and measuring an electrical property to detect a presence of the at least one toxic gas.